Stock Analiz

GoodRx Holdings, Inc. (GDRX) stock forecast and price target

Price $3.56 · data as of November 13, 2026

12-month price target

Average target$3.95
Upside / downside+11.0%
Analysts12
ConsensusHold
Low $2.65Average $3.95High $5.00

Gold marker: average target · white marker: today’s price ($3.56)

Analyst ratings

Strong buy 1Buy 3Hold 8Sell 0Strong sell 2

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$0.30−13.4%$798M
Next fiscal year
ends December 31, 2027
$0.35+16.2%$836M
Quarter after
ends December 31, 2026
$0.08−11.7%$202M

Consensus of the analysts covering GoodRx, updated daily. In the last 30 days 4 estimates were raised and 5 lowered.

Our model vs. Wall Street

Analysts see 11.0% upside over 12 months. Our discounted cash flow model with moderate assumptions puts GoodRx’s intrinsic value about 33% below today’s market value, and it scores 1.4 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.

Frequently asked questions

What is the GoodRx stock price target?

The average 12-month target from 12 analysts is $3.95, 11.0% above the current price of $3.56 Targets range from $2.65 to $5.00.

Is GoodRx a buy according to analysts?

The consensus rating is “Hold” (1 strong buy, 3 buy, 8 hold, 2 strong sell). Ratings are opinions, not guarantees; this is not investment advice.

How much is GoodRx expected to earn?

Analysts expect EPS of $0.30 for the fiscal year ending December 31, 2026 and $0.35 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.